a hrefhttps:www.fiercepharma.compharmahow-2-fda-citations-complicate-hengrui-elevar-push-liver-cancer-combo-approval hreflangenHow 2 FDA citations complicate Hengrui, Elevars push for liver cancer combo approvala

Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second citation stands in the way of the company and its partner Elevar Therapeutics fourth attempt at an approval for their liver cancer combination.